Joana Goncalves, Chief Medical Officer of Oruka Therapeutics (NASDAQ:ORKA), sold 7,000 shares of common stock for $432,935 on May 15, 2026, per an SEC filing.
The sales ranged from $60.93 to $63.52 per share and were executed under a Rule 10b5-1 trading plan established on September 19, 2025.
The insider sale comes as Oruka's stock has surged over 515% in the past year, with a market cap of $3.72 billion.
Prior to the sales, Goncalves acquired 7,000 shares through employee stock options and warrants on the same day, totaling $51,240.
Transaction details:
Sales:
- 4,800 shares at average $61.5614 (range $60.93-$61.90)
- 2,100 shares at average $62.423 (range $62.02-$62.89)
- 100 shares at $63.52
Acquisitions:
- 3,500 shares from options at $6.84
- 3,500 shares from warrants at $7.80
Post-transactions, Goncalves directly holds 33,377 shares.
In other news, Oruka reported positive interim results from EVERLAST-A Phase 2a trial for ORKA-001. Analysts raised price targets: H.C. Wainwright to $120, Clear Street to $131, Barclays to $160.
